India's Biocon exits enzymes business

Biocon sells its enzymes business to Denmark's Novozymes for $115 million in an attempt to become a more focussed biotechnology player.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES